4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reaffirmed at Weiss Ratings
Weiss Ratings reaffirmed their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report report published on Saturday morning,Weiss Ratings reports. FDMT has been the topic of several other research reports. Chardan Capital restated a “buy” rating and set a $39.00 target price on shares of 4D Molecular […]
More Stories
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...
Your Brain’s Secret Defense Against Alzheimer’s
By Brendon Fallon and Lynn Xu For many people, Alzheimer’s disease casts an increasingly large shadow as mental fog, forgotten...
Your Brain’s Secret Defense Against Alzheimer’s
By Brendon Fallon and Lynn Xu For many people, Alzheimer’s disease casts an increasingly large shadow as mental fog, forgotten...
Rivian Recalls Nearly 35,000 Delivery Vans Over Seat Belt Misuse Issue
By Rob Sabo Electric vehicle (EV) manufacturer Rivian Automotive announced on Dec. 3 it is recalling 34,824 delivery vans due...
Rivian Recalls Nearly 35,000 Delivery Vans Over Seat Belt Misuse Issue
By Rob Sabo Electric vehicle (EV) manufacturer Rivian Automotive announced on Dec. 3 it is recalling 34,824 delivery vans due...